Clinical Trial Update: SinTilimab After Radiation (STAR Study) [Phase 2]

View source ↗

Summary

Phase 2 STAR trial evaluating SinTilimab after radiation for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Carcinoma, Non-Small Cell Lung | Phase 2 | Status: COMPLETED